Superworth

DexCom EV/EBIT DXCM

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Nov 3, 2026
25.8×
7-year median
101×
Against its 7-year history
3rd
percentile: 0 is its lowest day, 100 its highest
7-year range
21.6× to 212×
Peer median
22.4×

DexCom's EV/EBIT is 25.8× as of Nov 3, 2026.

That is below its 7-year median of 101×, lower than on 97% of days in the last 7 years.

Over that time it ranged from 21.6× in May 2026 to 212× in Jul 2020.

The median for 9 medical device stocks of a similar size is 22.4×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far25.8×21.6×37.6×
202534.8×28.5×58.2×
202450.4×37.1×90.9×
202388.6×61.3×167×
2022163×102×193×
2021139×107×168×
2020117×99.5×212×

Against its peers

Companies in Medical - Devices nearest DexCom's size, closest first, today.

Where DexCom ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on DexCom

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.